Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

20151,222 citationsJournal Articlebronze Open Access

Authors

Marc J. M. Bonten · Oklahoma State University Center for Health Sciences

Susanne M. Huijts · University Medical Center Utrecht

Marieke Bolkenbaas · Oklahoma State University Center for Health Sciences

Chris Webber · Pfizer (United Kingdom)

Scott D. Patterson · Pfizer (United States)

Samantha Gault · Pfizer (United Kingdom)

Cornelis H. van Werkhoven

Abstract

Among older adults, PCV13 was effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing community-acquired pneumonia from any cause. (Funded by Pfizer; CAPITA ClinicalTrials.gov number NCT00744263.).

Topics & Keywords

Pneumonia and Respiratory Infections Respiratory viral infections research Pneumocystis jirovecii pneumonia detection and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 12, pp. 1114-1125

DOI: 10.1056/nejmoa1408544

Field-Weighted Citation Impact: 106.95